Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HTR6 | P50406 | 16/20 | 0.58 |
| ▸ | PTGS1 | P23219 | 1/20 | 0.48 |
| ▸ | PTGS2 | P35354 | 1/20 | 0.48 |
| ▸ | HTR1A | P08908 | 1/20 | 0.45 |
| ▸ | DRD2 | P14416 | 1/20 | 0.45 |
| ▸ | HTR1D | P28221 | 1/20 | 0.45 |
| ▸ | HTR1B | P28222 | 1/20 | 0.45 |
| ▸ | HTR1E | P28566 | 1/20 | 0.45 |
| ▸ | HTR1F | P30939 | 1/20 | 0.45 |
| ▸ | HTR7 | P34969 | 1/20 | 0.45 |
| ▸ | DRD3 | P35462 | 1/20 | 0.45 |
| ▸ | PTGDR | Q13258 | 2/20 | 0.43 |
| ▸ | PTGDR2 | Q9Y5Y4 | 2/20 | 0.43 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3566087 | 0.92 | HTR6 (0.60) | HTR6HTR1ADRD2HTR1DHTR1B | |
| SCHEMBL3563475 | 0.92 | HTR6 (0.47) | HTR6PTGS1PTGS2PTGDRPTGDR2 | |
| SCHEMBL3565226 | 0.90 | HTR6 (0.56) | HTR6HTR1ADRD2HTR1DHTR1B | |
| SCHEMBL3555051 | 0.90 | HTR6 (0.58) | HTR6HTR1ADRD2HTR1DHTR1B | |
| SCHEMBL3564114 | 0.90 | HTR6 (0.58) | HTR6HTR1ADRD2HTR1DHTR1B | |
| SCHEMBL3560763 | 0.90 | HTR6 (0.72) | HTR6HTR1ADRD2HTR1DHTR1B | |
| SCHEMBL3556775 | 0.88 | HTR6 (0.44) | HTR6PTGDRPTGDR2 | |
| SCHEMBL3563804 | 0.88 | HTR6 (0.48) | HTR6PTGDRPTGDR2 | |
| SCHEMBL3556528 | 0.87 | HTR6 (0.53) | HTR6PTGS1PTGS2HTR1ADRD2 | |
| SCHEMBL3557713 | 0.86 | PTGDR2 (0.49) | HTR6PTGDRPTGDR2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1567492-B1 | N-ARYLSULFONYL-3-AMINOALKOXYINDOLES | SUVEN LIFE SCIENCES LTD (IN) | 2013-05-22 | — | — | EP | claimed |
| US-7507835-B2 | N-arylsulfonyl-3-aminoalkoxyindoles | SUVEN LIFE SCIENCES LTD. (IN) | 2009-03-24 | — | — | US | claimed |
| US-20060173193-A1 | N-arylsulfonyl-3-aminoalkoxyindoles | SUVEN LIFE SCIENCES LIMITED (IN) | 2006-08-03 | — | — | US | claimed |
| EP-1567492-B1 | N-ARYLSULFONYL-3-AMINOALKOXYINDOLES | SUVEN LIFE SCIENCES LTD (IN) | 2013-05-22 | — | — | EP | disclosed |
| US-7718690-B2 | N-arylsulfonyl-3-aminoalkoxyindoles | RAMAKRISHNA VENKATA SATYA NIROGI | 2010-05-18 | — | — | US | disclosed |
| US-20090131507-A1 | N-arylsulfonyl-3-aminoalkoxyindoles | SUVEN LIFE SCIENCES LIMITED (IN) | 2009-05-21 | — | — | US | disclosed |
| US-7507835-B2 | N-arylsulfonyl-3-aminoalkoxyindoles | SUVEN LIFE SCIENCES LTD. (IN) | 2009-03-24 | — | — | US | disclosed |
| US-20060173193-A1 | N-arylsulfonyl-3-aminoalkoxyindoles | SUVEN LIFE SCIENCES LIMITED (IN) | 2006-08-03 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090131507-A1 | N-arylsulfonyl-3-aminoalkoxyindoles | HTR3C, HTR3A, AANAT | HTR6 56/4885PTGS1 1894/4885PTGS2 1969/4885 |
| US-20060173193-A1 | N-arylsulfonyl-3-aminoalkoxyindoles | HTR3C, HTR3A, AANAT | HTR6 56/4885PTGS1 1894/4885PTGS2 1969/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.